The ongoing Covid-19 pandemic has yielded an unexpected advancement in the pharmaceutical industry with the approval of the first mRNA vaccines, which GlobalData expects will soon impact other indications.
This historical landmark could have significant implications, primarily in the oncology market since mRNA vaccines were being exclusively investigated in infectious and oncology diseases prior to the pandemic. Historically, mRNA vaccines were of interest in the oncology setting because multiple biomarkers could be targeted by this novel mechanism.
Given the current role of immunotherapies in oncology, mRNA vaccines pose a novel approach to trigger immune reactions against cancer cells. However, the novelty of mRNA vaccines has raised regulatory and manufacturing questions in addition to clinical limitations.
Covid-19 approvals showcase potential of mRNA vaccines
The recent approvals of Pfizer / BioNTech’s and Moderna’s mRNA vaccines in healthy patients, complemented by the historically unmatched magnitude to reach healthy patients worldwide, has helped surpass many barriers for mRNA vaccines while highlighting this novel mechanism of action. GlobalData expects this will propagate a new epicenter of interest in pursuing this drug class in oncology.
Currently, there are 44 ongoing clinical trials exploring mRNA vaccines, of which 23 are investigating infectious diseases. This includes Covid-19, which accounts for 60% of those clinical trials. Interestingly, only four out of the 44 clinical trials have made it to Phase III as a result of the sudden and immense demand to prevent the spread of Covid-19.
From an oncology viewpoint, the current pandemic will still serve to provide essential real-world data about the tolerability and effects of mRNA vaccines, since despite their approval and initial vaccination rollout, the long-term efficacy and side effects are still to be understood. As more data are gathered on these vaccines, GlobalData expects an increasing interest in bringing them into the oncology sector.
Key opinion leaders (KOLs) interviewed by GlobalData have repeatedly shown interest in novel mechanisms of action, particularly in immunotherapy. Prior to the pandemic, mRNA vaccines were one of many promising drug classes that were being explored equally with each other, with no expectation about which would be the next to impact the market. However, the sudden rise of mRNA vaccines makes it a prime candidate since there is a current spotlight on this drug class.
A supporting argument for the interest in mRNA vaccines is that out of the 21 ongoing non-infectious disease clinical trials that are exploring mRNA vaccines, all are being developed for oncology indications. Of these 21 trials, only seven are in Phase II, which demonstrates the relatively early stage of mRNA vaccines in oncology. Interestingly, the most represented company in these clinical trials is BioNTech, with seven of the 21 trials, followed by Roche/Genentech with three clinical trials and Moderna Inc with two clinical trials.
Image Credit: Shutterstock
Post by Amanda Scott, NA CEO. Follow her on twitter @tantriclens
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News
Large Number of COVID-19 Survivors Will Experience Cognitive Complications
A research review led by Oxford Brookes University has found a large proportion of COVID-19 survivors will be affected by neuropsychiatric and cognitive complications. Psychologists at Oxford Brookes University and a psychiatrist from Oxford [...]
Virus detection method is versatile and accessible
A safe, fast and cheap testing method that uses magnetic nanoparticles to detect viruses in both clinical and wastewater samples has been developed by KAUST researchers. The centrifuge-free approach is compatible with magnetic bead-based [...]
First complete coronavirus model shows how the spike proteins move cooperatively
The COVID-19 virus holds some mysteries. Scientists remain in the dark on aspects of how it fuses and enters the host cell; how it assembles itself; and how it buds off the host cell. [...]
Researchers discover potential new therapeutic targets on SARS-CoV-2 Spike protein
The COVID-19 pandemic has prompted considerable investigation into how the SARS-CoV-2 Spike protein attaches to a human cell during the infection process, as this knowledge is useful in designing vaccines and therapeutics. Now, a [...]
Tricking the novel coronavirus with a fake ‘handshake’
Scientists have developed protein fragments—called peptides—that fit snugly into a groove on the SARS-CoV-2 Spike protein that it would normally use to access a host cell. These peptides effectively trick the virus into "shaking hands" with a replica rather than with [...]
Researchers reveal genetic predisposition to severe COVID-19
HSE University researchers have become the first in the world to discover genetic predisposition to severe COVID-19. The results of the study were published in the journal Frontiers in Immunology. T-cell immunity is one of [...]
What Pseudoviruses Bring to the Study of SARS-CoV-2
When SARS-CoV-2 first began spreading across the globe, not every lab was equipped to study it directly. The virus behind the current pandemic is highly pathogenic and transmissible, leading the US Centers for Disease [...]
Covid-19: Future targets for treatments rapidly identified with new computer simulations
esearchers have detailed a mechanism in the distinctive corona of Covid-19 that could help scientists to rapidly find new treatments for the virus, and quickly test whether existing treatments are likely to work with [...]
Almost Half of Coronavirus Sufferers Report Depression
Almost half of people testing positive for coronavirus have reported symptoms of depression, according to a new study published in the International Journal of Environmental Research and Public Health. Researchers from Bangladesh, the United States [...]
Six previously FDA-approved drugs appear promising against SARS-CoV-2 in laboratory testing
A team of investigators from the Republic of China has discovered that 6 drugs previously approved by the US Food and Drug Administration (FDA) for other indications could be repurposed to treat or prevent [...]
Graphene could one day be used to make quick, reliable tests for viruses like SARS-CoV-2
Graphene is a layer of carbon only one atom thick. Since it was first isolated in 2004, it has found applications in strengthening materials, accelerating electronics, and boosting performance in batteries, among others. It [...]
UK spots 33 cases of ANOTHER Covid variant
Another Covid variant that could dodge vaccine-triggered immunity has been identified in the UK, scientists say. The strain — called B.1.525 — has been spotted 33 times already but experts say this could be [...]
Spotlight on mRNA vaccines: Covid-19 approvals highlight a novel competitive landscape in oncology
The ongoing Covid-19 pandemic has yielded an unexpected advancement in the pharmaceutical industry with the approval of the first mRNA vaccines, which GlobalData expects will soon impact other indications. This historical landmark could have [...]
New AI Tool Can Thwart Coronavirus Mutations
USC researchers have developed a new method to counter emergent mutations of the coronavirus and hasten vaccine development to stop the pathogen responsible for killing thousands of people and ruining the economy. Using artificial [...]
Pfizer vaccine: Single dose ‘90 per cent effective after 21 days’
A single dose of the Pfizer coronavirus vaccine is “highly protective” after three weeks, according to a study. Researchers at the University of East Anglia (UEA) said the coronavirus vaccine developed by Pfizer and BioNTech was still effective [...]
COVID-19 Attack On Brain, Not Lungs, Triggers Severe Disease In Mice
Summary: Mice exposed to COVID-19 through the nasal passage, researchers noted a rapid and escalated attack on the brain by the virus that triggered a more severe outcome of the infection, even after the lungs [...]
